Comparative effectiveness and cost of adding rituximab to first-line chemotherapy for elderly patients diagnosed with diffuse large B-cell lymphoma.
BACKGROUND: Clinical trials indicate that rituximab improves the survival of patients with diffuse large B-cell lymphoma (DLBCL). Economic models using multiple data sources, including clinical trials for survival outcomes, have projected cost offsets/savings and favorable cost-effectiveness associ...
Main Authors: | Griffiths, R, Gleeson, M, Mikhael, J, Dreyling, M, Danese, MD |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2012
|
Similar Items
-
Comparative effectiveness and cost of adding rituximab to first-line chemotherapy for elderly patients diagnosed with diffuse large B-cell lymphoma
by: Griffiths, R, et al.
Published: (2012) -
Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma.
by: Griffiths, R, et al.
Published: (2011) -
Impact on Medical Cost, Cumulative Survival, and Cost-Effectiveness of Adding Rituximab to First-Line Chemotherapy for Follicular Lymphoma in Elderly Patients: An Observational Cohort Study Based on SEER-Medicare.
by: Griffiths, R, et al.
Published: (2012) -
Second-line therapy in diffuse large B-cell lymphoma (DLBCL): treatment patterns and outcomes in older patients receiving outpatient chemotherapy.
by: Danese, MD, et al.
Published: (2016) -
Racial differences in treatment and survival in older patients with diffuse large B-cell lymphoma (DLBCL)
by: Griffiths, R, et al.
Published: (2010)